Journal
CELL
Volume 165, Issue 7, Pages 1621-1631Publisher
CELL PRESS
DOI: 10.1016/j.cell.2016.05.024
Keywords
-
Categories
Funding
- Bill and Melinda Gates Foundation [OPP50714, OPP1040732, 1032144]
- National Institutes of Health [DP1DA033263]
Ask authors/readers for more resources
While the search for an efficacious HIV-1 vaccine remains elusive, emergence of a new generation of virus-neutralizing monoclonal antibodies (mAbs) has re-ignited the field of passive immunization for HIV-1 prevention. However, the plasticity of HIV-1 demands additional improvements to these mAbs to better ensure their clinical utility. Here, we report engineered bispecific antibodies that are the most potent and broad HIV-neutralizing antibodies to date. One bispecific antibody, 10E8(V2.0)/iMab, neutralized 118 HIV-1 pseudotyped viruses tested with a mean 50% inhibitory concentration (IC50) of 0.002 mu g/mL. 10E8(V2.0)/iMab also potently neutralized 99% of viruses in a second panel of 200 HIV-1 isolates belonging to clade C, the dominant subtype accounting for similar to 50% of new infections worldwide. Importantly, 10E8(V2.0)/iMab reduced virus load substantially in HIV-1-infected humanized mice and also provided complete protection when administered prior to virus challenge. These bispecific antibodies hold promise as novel prophylactic and/or therapeutic agents in the fight against HIV-1.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available